Skip to main content

Bibliografie: literatuurlijst HPU/KPU

We willen iedereen bedanken die bijgedragen heeft bij het tot stand komen van deze bibliografie. Wanneer u een literatuurreferentie tegenkomt, die niet in deze lijst voorkomt, mail die dan naar
Auteurs worden eveneens uitgenodigd hun publicaties te mail of te sturen. We zullen ze dan meteen in de lijst opnemen.

Andersen, D.J. en G.G. Shaw (1974) Hyperglycemia produced by the polyamines spermine and spermidine. Br. J. Pharm. 52, 205-211.
Anderson, K.E. (1992) The porphyrias. In: Cecil Textbook of Medicine. Wijngaarden e.a. red. Saunders, Philadelphia.
Anonymus (1973) The “mauve factor” in schizophrenia. (Author unknown) Medical World News p. 49, 14 December 1973.
Anonymus (2003) An epidemiological study on the relationship between selenium and thyroid function in areas with different iodine intake. Zhonghua Yi Xue Za Zhi (Chinese Medical Journal no. X, dec. 2003) 83, 2036-2039.
Atamna H, Killilea DW, Killilea AN, et al. (2002) Heme deficiency may be a factor in the mitochondrial and neuronal decay of aging. Proceedings of the National Academy of Science 99, 14807-14812.
Audhya, T. (2002) Defeat Autism now (DAN). Conference San Diego California, 25 October 2002.
Awruch J, Frydman B. (1973) Peracid oxidation of 2,4-dimethyl-3-ethylpyrrole (kryptopyrrole). Tetrahedron Letters 28, 2611-2614.
Berek I, Huszak I, Durko I. (1975) The effect of kryptopyrrole on the porphyrin auxotrophic strains of bacillus subtilis. Experientia 31, 185.
Bibus, D.G., R.T. Holman et W.J. Walsh (2000) Fatty acid profiles of schizophrenic phenotypes. 91st. AOCS Annual Meeting and Expo, San Diego, California.
Bonnet, P.L., C.C. Pfeiffer et B.J. Aston (1980) Copper, the ABO blood system and the schizophrenias. Brain Bio Center, 1980.
Brame, C.J. , R.G. Salomon, J.D. Morrow en J.L. Roberts (1999) Identification of extremely reactive ketoaldehydes (isolevuglandins) as product of the isoprostane pathway and characterization of their lysyl protein adducts. J. Biol. Chem. 274, 13139-13146.
Brodie, M.J., D.J. Graham, G.G. Thompson, M.R. Moore en A. Goldberg (1976) The porphyrinogenic effect of kryptopyrrole in the rat and the occurence of urinary kryptopyrrole in human hereditary hepatic porphyria. Clin. Sci. Mol. Med. 50, 431-434.
Brown, G.M. e.a. (1969) A re-evaluation of glucose tolerance in schizophrenias. J. Psychiat. Res. 6, 261-270.
Busnel, J. (1999) Bekkeninstabiliteit. Van Holkema & Warendorf, 97 pp.
Chugh, T.O., R.K. Dhingra, R.C. Gulati en J.C. Bathla (1973) Copper metabolism in schizophrenia. Int. J. Med. Res. 61, 1147-1152.
Clift S. A complete guide to pyroluria. (Submitted as coursework for the Nutrition Consultants Diploma, Institute for Optimum Nutrition, 1996)
Closs, K., N. Wad en E. Ose (1967) The “pink spot” in schizophrenia. Nature 214(87), 483.
Cruz, R. en W.H. Vogel (1978) Pyroluria: a poor marker in chronic schizophrenia. Am. J. Psychiatry 135, 1239-1240.
Cutler, M.G., D.J. Graham en M.R. Moore (1990) The mauve factor of porphyria, 3-ethyl-5-hydroxy-4,5-hydroxy-4,5-dimethyl-delta-3-pyrroline-2-one: effects on behaviour of rats and mice. Pharmacol. Toxicol. 66, 66-68.
Cutler P. Pyridoxine and trace element therapy in selected clinical cases. (1974) Journal of Orthomolecular Psychiatry 3, 89-95, 1974.
Donnay, A. en G.E. Ziem (1995) Protocol for evaluating disorder of porphyrin in chemically sensitive patients. MCS Referral & Resources, Baltimore.
Denson R. (1968) Lysergide therapy and the mauve factor. Acta Psychiatrica Scandinavica 44, 280-288.
Dühring, C. (1996) Toward a unifying metabolic factor for MCS. Our toxic times 7, 15.
Durko, I, I. Berek en I. Husak (1975) Effects of kryptopyrrole on porphyrin synthesis in Bacillus subtilis 168. Hoppe-Seylers Z. Physiol. Chem. 356, 1679-1684.
Durko I, Berek I, Huszak I. (1976) On complex formation between haem and oxidation products of kryptopyrrole, as a possible explanation for enhanced porphyrin synthesis of bacillus subtilis 168 strain. Proceedings of the International Congress of Biochemistry 10, 104.
Durko I, Engelhardt J, Szilard J, et al. (1984) The effect of haemodialysis on the excretion of the mauve factor in schizophrenia. Journal of Orthomolecular Psychiatry 13, 222-232.
Edelman E. (1996) Natural Healing for Schizophrenia, Borage Books, Eugene, Oregon.
Ellman, G.L., R.T. Jones, en R.C. Rychert (1968) Mauve spot and schizophrenia. Am. J. Psychiatry 125, 849-851.
Evans, G.W. (1980) Normal and abnormal zinc absorption in man and animals. Nut. Reviews 38, 137-141.
Frydman RB, Tomaro ML, Wanschelbaum A, et al. (1972) The enzymatic oxidation of porphobilinogen. FEBS Letters, 203-206.
Gebel, L. (1973) Occurrence of the mauve factor in schizophrenia. Psychiatr. Pol. 7, 153-159.
Gendler, P.L., H.A. Duhan en H. Rapoport (1978) Hemopyrrole and kryptopyrrole are absent from the urine of schizophrenics and normal persons. Clin. Chem. 24, 230-233.
Goddijn-Wessel, T.A.W. (1996) Hyperhomocysteinemia: a risk factor for placental abruption or infarction. Eur. J. Obst. Gynecol. Repr. Biol. 66, 23-29.
Gorchein, A. (1980) Urine concentration of 3-ethyl-5-hydroxy-4,5-dimethyl[delta-3-]pyrrolin-2-one (‘mauve factor’) is not causally related to schizofrenia or to acute intermittent porphyria. Clin. Science 58, 469-476.
Gorchein, A., L.D. Mitchell en A.T. Rogers (1979) Pharmalogical properties of kryptopyrrole and its oxidation products on isolated sciatic nerve of rat and on guinia-pig ileum. Br. J. Pharmacol. 65, 23-27.
Gorchein, A. en A.T. Rogers (1979) The ‘Mauve factor’ of schizophrenia and porphyria, 5-hydroxyhaemopyrrole lactam, has low pharmalogical potency on guina-pig ileum. Experienta 35, 1078-1079.
Gorchein A., Mitchell L.D. en Rogers AT. Pharmacological properties of kryptopyrrole and its oxidation products on isolated sciatic nerve of rat and on guinea-pig ileum. British Journal of Pharmacology 65, 23-27, 1979.
Gorchein A. en Rogers A.T. The ‘mauve factor’ of schizophrenia and porphyria, 5-hydroxyhaemopyrrole lactam, has low pharmacological potency on guinea-pig ileum. Experientia 35, 1078-1079, 1979.
Gorchein A. Urine concentration of 3-ethyl-5-hydroxy-4,5-dimethyl-[delta 3]-pyrrolin-2-one (‘mauve factor’) is not causally related to schizophrenia or to acute intermittent porphyria. Clinical Science 58, 469-476, 1980.
Graaf, T. de, H. van Rossum (2000) Hebt u HPU?; de ontdekking van een vrouwenziekte. Mix Media, Harderwijk, 205 pp.
Graff, H. en A. Hanford (1961) Celiac syndrome in the case history of five schizophrenics. Psychiatric Quarterly 35, 306-313.
Graham D.J.M, Moore M.R., Thompson G.G., et al. (1976) The effect of 4-ethyl-5-hydroxy-3,5-dimethyl-[delta 3]-pyrrolin-2-one on porphyrin synthesis in the rat. Biochemical Society Transactions (Great Britain) 4, 1089-1091.
Graham D.J.M., Thompson G.G., Moore M.R., et al. (1977) The effect of 4-ethyl-5-hydroxy-3,5-dimethyl-[delta 3]-pyrrolin-2-one on haem metabolism in the rat. Biochemical Society Transactions, (507th Meeting, Cardif) 5, 1468-1470.
Graham D.J.M., Brodie M.J., Moore M.R., et al. (1977) Quantitation of a urinary pyrrolic metabolite found in excess in acute intermittent porphyria. Scottish Medical Journal 22, 243.
Graham D.J.M. (1978) Quantitative determination of 3-ethyl-5-hydroxy-4,5-dimethyl-[delta 3]-pyrrolin-2-one in urine using gas-liquid chromatrography. Clinica Chimica Acta 85, 205-210.
Graham D.J.M., Brodie M.J., McColl K.E.L., et al. (1979) Quantitation of 3-ethyl-5-hydroxy-4,5-dimethyl-[delta 3]-pyrrolin-2-one in the urine of patients with acute intermittent porphyria. European Journal of Clinical Investigation 9, 49-53.
Graham D.J.M., Thompson G.G., Moore M.R., et al. (1979) The effects of selected monopyrroles on various aspects of heme biosynthesis and degradation in the rat. Archives of Biochemistry and Biophysics 197, 132-138.
Grinstein, M., M.F. de Sancovich en H.A. Sancovich (1978) The isolation of another new compound from the urine of humans with porphyria cutanea tarda. Biochim. Biophys. Acta 543, 583-585.
Hallert, C. en G. Sedvall (1983) Improvement in cntral monoamine metabolism in adult coeliac patiënt starting gluten-free diet. Psychological Medicine 13, 267-271.
Hatch T, Lascelles J. (1972) Accumulation of porphobilinogen and other pyrroles by mutant and wild type Rhodopseudomonas speroides: regulation by heme. Archives of Biochemistry and Biophysics 150, 147-153.
Hamfelt A., Wetterberg L. (1969) Pyridoxal phosphate in acute intermittent porphyria. Annals of the New York Academy of Sciences 166, 361-364, 1969.
Heleniak, E.P. en S.W. Lamola (1986) A new prostaglandin disturbance syndrome in schizophrenia: delta-6-pyroluria. Med. Hypotheses 19, 333-338.
Heufelder, A.E. (2001) Kryptopyrrolurie. Comed 2001, 5.
Heufelder, A.E. (2002) Kryptopyrrolurie. Orthomolecular Medizin 25, 110-111.
Hinshaw C.T. (1981) Urinary pyrrole (mauve factor malvaria, pyrroluria, kryptopyrrole). Review, (Bimonthly publication: The Olive W. Garvey Center for the Improvement of Human Functioning, Wichita, September 1981.
Hoffer, A. (1962) Nicotinic acid and nicotinamide in treatment of schizophrenia. In: Niacin therapy in psychiatry. C.C. Thomans, Springfield, Illinouis.
Hoffer A. (1963) The presence of malvaria in some mentally retarded children. American Journal of Mental Deficiency 67, 730-732.
Hoffer A. (1965) A comparison of psychiatric inpatients and outpatients and malvaria. International Journal of Neuropsychiatry 1,430-432.
Hoffer A. (1965) Malvaria, schizophrenia and the HOD test. International Journal of Neuropsychiatry 2, 175-178.
Hoffer A. (1965) D-Lysergic acid diethylamide (LSD): a review of its present status. Clinical Pharmacology and Therapeutics 6, 183-255.
Hoffer, A. (1966) The presence of malvaria in some mentally retarded children. Amer. J. Ment. Def. 67, 730-732.
Hoffer, A. (1966) Malvaria and the law. Psychosomatics 7, 303-310.
Hoffer, A. (1967) A program for the treatment of alcoholism: LSD, malvaria and nicotinic acid. In: The use of LSD in psychotherapy and alcoholism. H.A. Abramson, editor; Bobbs-Merril, New York, Howard W. Sams and Co., Inc, Indianapolis; pp. 343-406.
Hoffer, A. (1967) Treatment of schizophrenia with a therapeutic program based upon nicotinic acid as the main variable. In: Molecular basis of some aspects of mental activity. Vol. II. O. Walaas, ed. Academic Press, New York.
Hoffer, A. (1970) The psychophysiology of cancer. J. Astma Research 8, 61-76.
Hoffer, A. (1971) Megavitamin B3 therapy for schizophrenia. Can. Psychiatric Assoc. J. 16, 499-504.
Hoffer, A. (1972) Treatment of hyperkinetic children with nicotinamide and pyridoxine. Can. Med. Assoc. J. 107, 111-112.
Hoffer, A. (1973) Mechanism of action of nicotinic acid and nicotinamide in the treatment of schizophrenia. In Orthomolecular Psychiatry, eds. Hawkins D, Pauling L. W.H. Freeman and Company, San Francisco. pp. 202-262, 1973.
Hoffer, A. (1976) Natural history and treatment of thirteen pairs of identical twins, schizophrenic and schizophrenic-spectrum conditions. J. Orthomolecular Psychiatry 5, 101-122.
Hoffer, A. (1979) Behavioral nutrition. Journal of Orthomolecular psychiatry 8,169-175.
Hoffer, A. (1983) Nutrition and behavior. In: Medical Applications of Clinical Nutrition, Bland J., editor, Keats Publishing, New Canaan, Connecticut; pp. 222-268, 1983.
Hoffer, A. (1989) Orthomolecular medicine for physicians. Keats Pub., New Canaan, Connecticut.
Hoffer, A. (1991) Orthomolecular medicine. In: Molecules in natural science and medicine, an encomium for Linus Pauling. Z.B. Maksic en M. Eckert-Maksic, ed. Ellis Horwood Ltd., Chichester, West Sussex. Great Brittain.
Hoffer, A. (1994) Vitamin B3 and schizophrenia: discovery, recovery, controversy. Quarry Press, Kingston, Ontaria.
Hoffer, A. (1994) Chronic schizophrenic patients treated ten years or more. J. Orthomolecular Medicine 9, 7-37.Hoffer, A. (1995) The discovery of kryptopyrrole and its importance in diagnosis of biochemical imbalances in schizophrenia and in criminal behavior. Journal of Orthomolecular Medicine 10, 3-7.
Hoffer, A. en M.J. Callbeck (1957) The hypocholesterolemic effect of nicotinic acid its relationship to the autonomic nervous system. J. Ment. Science 103, 810-820.
Hoffer, A. en M.J. Callbeck (1959) Effect of nicotinic acid on liver function and leucocytes. Can. Med. Ass. J. 80, 736-737.
Hoffer, A. en M.J. Callbeck (1960) Drug-induced schizophrenia. J. Ment. Science 106, 138-159.
Hoffer, A. P.O. O’Reilly en M.J. Callbeck (1959) Specificity of the hypocholestrolemic activity of nicotinic acid. Dis. Nerv. Syst. 20, 286-288.
Hoffer, A., H. Osmond, M.J. Callbeck en I. Kahan (1957) Treatment of schizophrenia with nicotinic acid and nicotinamide. J. Clin. Exp. Psychopathol. 18, 131-158.
Hoffer A. en Mahon M. (1961) The presence of unidentified substances in the urine of psychiatric patients. Journal of Neuropsychiatry 2, 331-362.
Hoffer A. en H. Osmond (1962) The association between schizophrenia and two objective tests. Canadian Medicial Association Journal 87, 641-646.
Hoffer, A, en H. Osmond (1963) Malvaria: a new psychiatric disease. Acta Psychiat. Scand. 39, 335-366.
Hoffer, A. en H. Osmond (1964) Treatment of schizofrenia with nicotinic acid – A ten year follow-up. Acta Psychiat. Scand. 40, 171-189.
Hoffer, A. en H. Osmond (1961) The relationship between an unknown factor (US) in the urine of subjects and HOD test results. J. Neuropsychiatry 2, 363-368.
Hoffer, A. en H. Osmond (1962) The association between schizofrenia and two onjective tests. Can. Med. Ass. J. 87, 641-646.
Hoffer, A. en H. Osmond (1963) Malviaria: A new psychiatric disease. Acta Psychiat. Scand. 39, 335-366.
Hoffer, A. en H. Osmond (1963) Malvaria: a new psychiatric disease. Acta Psychiatrica Scandinavica 39, 335-366.
Hoffer, A. en H. Osmond (1966) How to live with schizophrenia. University Books, New York.
Hoffer, A. en H. Osmond (1967) The hallucinogens, Academic Press, New York.
Hoffer A., Walker M. (1996) Putting It All Together: The New Orthomolecular Nutrition. Keats Publishing, New Canaan, 1996.
Hoffer, A., H. Kelm en H. Osmond (1975) The Hoffer-Osmond diagnostic test. RE Kriger Pub. & Co., Hungtington, New York.
Hoft E. (1967) The autoxidation of alkylpyrroles. Tetrahedron Letters 32, 3041-3044.
Horobin, D.F. (1977) Schizophrenia as a prostaglandin deficiency disease. Lacet I, 936-937.Huszak I, Durko I, Karsai K. (1972) Experimental data to the pathogenesis of cryptopyrrole excretion in schizophrenia. Acta Physiologica Academiae Scientiarum Hungaricae 42,79-86, 1972.
Irvine D.G. (1961) Apparently non-indolic erhlich-positive substances realted to mental illness. Journal of Neuropsychiatry 2, 292-305.
Irvine D.G. (1963) Mauve factor and 6-sulfoxyskatole: two biochemical abnormalities associated with specific measures of psychiatric disease. Clinical Chemistry 9, 444-445.
Irvine D.G. (1969) Identification of kryptopyrrole in human urine and its relation to psychosis. Nature 224, 811-813.
Irvine D.G. (1973) Kryptopyrrole in molecular psychiatry. In: Orthomolecular Psychiatry, eds. Hawkins D, Pauling L. W. H. Freeman and Company, San Francisco; pp. 146-178.
Irvine D.G. (1974) Kryptopyrrole and other monopyrroles in molecular neurobiology. In: International Review of Neurobiology. Vol. 16; Pfeiffer C.C., Smythies J.R., pp. 145-182 (Academic Press, 1974)
Irvine D.G. (1976) Autotransfer chromatography in the characterization of pyrroles: Chemistry of multiple-spot phenomena. J. Chromatogr. 123, 69-78.
Irvine D.G. (1976) Clinical, EEG and biochemical correlates of hydroxyhemopyrrolenone excretion. Proceedings of the 22nd Annual Psyciatric Research Meeting. Saskatoon, Saskatchewan, May 1977. Hether RW, ed. pp. 59-60 (Saskatoon Psychiatric Research Division, 1977).
Irvine, D.G. (1978) Hydroxy-hemopyrrolenone, not kryptopyrrole, in the urine of schizophrenics and porphyrics. Clin. Chem. 24, 2069-2670.
Irvine, D.G. (19..) Kryptopyrrole and other monopyrroles in molecular neurobiology. pp. 145-183.
Irvine D.G., Anderson M.E. (1965) Autotransfer chromatography: facile two-dimensional chromatography in which the stationary phase is changed. Journal of Chromatography 20, 541-545.
Irvine, D.G. (1976) Autotransfer chromatography in the characterization of pyrroles. Chemistry of multiple-spot phenomena. J. Chromatogr. 123, 69-78.
Irvine D.G. (1978) Hydroxy-hemopyrrolenone, not kryptopyrrole, in the urine of schizophrenics and porphyrics. Clinical Chemistry 24, 2069-2070.
Irvine D.G. (1978) Preliminatry characterization of a fecal pigment associated with hydroxyhemopyrrolenone excretion. Proceedings of the 23rd Annual Psychiatric Research Meeting, Saskatchewan pp. 26-28; April, 1978.
Irvine DG. Pyrroles in neuropsychiatric and porphyric disorders: confirmation of a metabolite structure by synthesis. Life Sciences 23, 983-990, 1978.
Irvine D.G., Bayne W. (1969) Simplification of autotransfer chromatography for the routine separation of endogenous and drug metabolites. Enzymologia Biologica et Clinica 10, 361-362.
Irvine D.G., Bayne W. (1970) Autotransfer chromatography combined with mass spectroscopy, for the characterization of pyrroles and indoles. Journal of Chromatography 48, 334-342, 1970.
Irvine, D.G. , W. Bayne, H. Miyashita en J.R. Majer (1969) Identification of kryptopyrrole in human urine and its relation to psychosis.Nature 224, 811-813.
Irvine D.G., Bayne W., Miyashita H. (1969) Kryptopyrroluria in mental disorders. Enzymologia Biologica et Clinica 10, 398.
Irvine DG, Ell D, Crichlow EC. Anticonvulsant and EEG activities of kryptopyrrole and a possible underlying neurochemical mechanism. Proceedings of the Fourth International Meeting of the International Society for Neurochemistry, Tokyo. p. 359, 1973.
Irvine, D.G., L. Wetterberg (1972) Kryptopyrrole-like substance inacute intermittent porphyria. Lancet II, 7788, 1201.
Irvine D.G., L. Wetterberg L. (1974) The dye-sensitized photooxygenation of hemopyrrole. Experientia 30, 587-588.
Irvine, D.G., D.L. Wilson (1976) Oxidized Monopyrroles in Porphyric Disorders and related conditions. Porphyrins in Human Diseases, 1st International Porphyrin Meeting, Freiburg/Br. 1975. pp. 217-224 (Karger, Basel 1976)
Isaacson H.R., Moran M.M., Hall A., et al. (1996) Autism: a retrospective outcome study of nutrient therapy. Journal of Applied Nutrition 48, 110-118.
Jackson J.A., Riordan H.D., Neathery S. (1990) Vitamin, blood lead, and urine pyrrole levels in Down syndrome. American Clinical Laboratory January-February: pp. 8-9.
Jackson J.A., Riordan H.D., Neathery S., et al. (1997) Urinary pyrrole in health and disease. Journal of Orthomolecular Medicine 12, 96-98.
Jackson J.A., Riordan H.D., Neathery S.S. (2000). Urine indican as an indicator of disease. Journal of Orthomolecular Medicine 15, 18-20.
Jackson J.A., Riordan H.D., Bramhall N., et al. (2002) Urine pyrroles in patients with cancer. (Manuscript in submission, by permission of author, Jan 2002).
Jackson J.A. Urinary screening procedure for pyroluria, utilizing kryptopyrrole standard.
Jacobson S.J., Rapoport H., Ellman G.L. (1975) The nonoccurrence of hemo- and kryptopyrrole in the urine of schizophrenics. Biological Psychiatry 10, 91-3.
Jaffe R, Kruesi OR. The biochemical-immunology window: a molecular view of psychiatric case management. Journal of Applied Nutrition 44(2), 26-42, 1992.
Kamsteeg, J. (1999) Kryptopyrrolurie. ‘Vrouwenkwaaltjes zijn echt niet altijd psychisch’. KEAC, Weert 62 pp.
Kamsteeg, J. (2000) HPU: a congenital defect of the metabolism. De Osteopaat, Juni 2000, p. 36-38.
Kamsteeg, J. (2000) HPU: stram en stijf van leden. Congres MBOG, Ede 7 oktober 2000.
Kamsteeg, J. (2002) HPU – Eine angeborene Porphyrinopathie. Zeitschrift für Umweltmedizin 10, 134-135.
<!–Summary/German (ist pdf)–>Kamsteeg, J. (2003) Die HPU-Krankheit. 8. Kongress für Orthomolekulare Medizin. Köln 3 mai 2003.
Kamsteeg, J. (2008) Abnormaler Verlauf der Porphyrinsynthese bei HPU-Pyrroliker. OM & Ernährung 124/2008, 53.
Kapuste, H. (1995) Pyrrolurie, Vitamin B6 und Zink: Therapeutische Erfolge und offene Fragen. Journal für Orthomolekulare Medizin 4.
Kapuste, H. (1998) Kryptopyrrolurie: Anregungen aus der Nutritionalen Medizin, GOMM, 1998, 9 pp.
Kapuste, H. (2003) Pyrrolurie, Vitamin B6 und Zink. Without Reference.27-36.
Kershner J, Hawke W. (1979) Megavitamins and learning disorders: a controlled double-blind experiment. Journal of Nutrition 109, 819-826.
Kimura, K. en J. Kumura (1965) Preliminary report on the metabolism of trace elements in neuropsychiatric disease. I. Zinc in schizophrenia. Proc. Jap. Acad. 41, 943-947.
Knoche, T. (2004) Die Pyrrolurie, der Vitamin B6 – Stoffwechsel und Folgeerkankungen. Umwelt-Echo jan. 2004, pp. 35.
Kraus R.T. (1995) An enigmatic personality: case report of a serial killer. Journal of Orthomolecular Medicine 10, 11-24.
Kosower N. (1968) Seizures in experimental porphyria. Nature 217:565-567, 1968.
Krischer, K. en C.C. Pfeiffer (1973) Biochemical relationship between kryptopyrrole (mauve factor) and trans-3-methyl-2-hexenoic acid (schizophrenia odor). Research Communications in Chemical Pharmacology. 5, 9-15.
Larson J.M. (1999) Depression-Free, Naturally. Ballantine Publishing Group, Random House, New York, 1999.
Ledochowski, M., B. Widner and D. Fuchs (2000) Fruktosemalabsorption. J. Ernährungsmed. 3, 10-14.
Ledochowski, M., B. Widner, Ch. Murr and D. Fuchs (2001) Decreased zinc in fructos malabsorbers. Clinical Chemistry 47, 745-747.
Ledochowski, M., Ch. Murr, C. Lass-Flörl and D. Fuchs (2001) Increased serum amylse and lipase in fructose malabsorbers. Clinica Chimica Acta 311, 119-123.
Lightner D.A., Crandall D.C. (1973) The dye-sensitized photooxygenation of kryptopyrrole. Experientia 29, 262-264.
Lightner D.A., Norris R.D., Kirk D.I., et al. (1974) The dye-sensitized photooxygenation of hemopyrrole. Experientia 30, 587-588.
Matosin-Matekalo, M., J.E. Mesonero, T.J. Laroche, M. Lacasa en E. Brot-Laroche (1999) Glucose and thyroid hormone co-regulate the expression if the intestinal fructose transporter GLUT5. Biochem. J. 339, 233-239.
McCabe D.L. (1983) Kryptopyrroles. Journal of Orthomolecular Psychiatry 12, 2-18.
McCarthy, J.L., R.L. Murphree (1960) Adrenal atrophy and thyroid inhibition following PABA. Proc. Soc. Exp. Biol. Med. 105, 515-517.
McGinnis, W. (2003) Urinary pyrrole (Mauve Factor): Metric for oxidative stress in behavioral disorders. The Linus Pauling Institute Annual Meeting in Portland, Oregon 21-24 mai 2003.
Mateus, M.L., Dos Santos A.P., en M.C. Batoreu (2002) Evidence of zinc protection against 2,5-hexanedione neurotoxicity: correlation of neurobehavioural testing with biomarkers of excretion. 6, 747-754.
Mehl, V. (2000) Pyrrolurie: eine weitgehend unbekannte, aber weitverbeitete Stoffwechsel-Besonderheit mit (u.a.) ADHD-Symptomatik. Die Akzente 2000, 23-25.
Moffett R.B. (1968) Central nervous system depressants. VIII. Pyrroles. Journal of Medicinal Chemistry 11, 1251-1252.
Moore M.R., Graham D.J.M. (1980) Monopyrroles in porphyria, psychosis and lead exposure. International Journal of Biochemistry 12, 827-832.
Moore M.R. Methodology for synthesis of HPL and related monopyrroles.
Neil, K. (1987) Pyrroluria – Vitamin B6 and zinc deficiency. Unknow. 2 pp.
O’Reilly P.O., M.J. Callbeck en A. Hoffer (1959) Sustained-release nicotinic acid (Nicospan). Effect on (1) cholestrol levels and (2) leukocytes. Can. Med. Ass. J. 80, 359-362.
O’Reilly P.O., Ernest M., Hughes G. (1965) The incidence of malvaria. British Journal of Psychiatry 111, 741-744.
O’Reilly P.O., Hughes G., Russell S., et al. (1965) The mauve factor: an evaluation. Diseases of the Nervous System 26, 562-568.
O’Reilly, P.O., M. Ernest en G. Hughes (1965) The incidence of Malvaria. Brit. J. Psychiatr. 111, 741-744.
Osmond H, Hoffer A. (1966) A comprehensive theory of schizophrenia. International Journal of Neuropsychiatry 2, 302-309.
Pepplinkhuizen, L. (1983) Disturbances of serine and glycine metabolism as a cause of episodiac acute polymorphous psychoses. Proefschrift Erasmus Universiteit Rotterdam 20 april 1983.
Pfeiffer CC, Mailloux R, Forsythe L. (1970)The Schizophrenias: Ours to Conquer. Biocommunications Press, Wichita, Kansas, 1988. Original publication by Pyramid Books.
Pfeiffer, C.C. (1972) Neurobiology of the trace metals, zinc and copper. Int. Rev. of Neurobiol., Academic Press, 1 sept. 1972.
Pfeiffer, C.C. en V. Iliev (1972) A study of zinc deficiency and copper excess in the schizoprhenias. Int. Rev. Neurobiol. Suppl. 1.
Pfeiffer, C.C. (1972) Blood histamine, basophil counts, and trace elements in the schizophrenias. Rev. Can. Biol. suppl. 1972, 73-76.
Pfeiffer, C.C., V. Iliev (1973) Pyrroluria, urinary mauve factor causes double deficiency of B6 and zinc in schizophrenics. Federation of American Societies for Experimental Biology Proceedings 32, 276. (Abstracts of a paper presented at the Federeation Annual Meeting)..
Pfeiffer C.C., Sohler A, Jenney C.H. and Iliev (1974) Treatment of pyroluric schizophrenia (malvaria) with large doses of pyridoxine and a dietary supplement of zinc. Journal of Orthomolecular Psychiatry 3, 292-300.
Pfeiffer, C.C. (1974) The clinical applications of zinc metabolism. In: Zinc metabolism. (E. Prasad, red. ) C.C. Thomas, Springfield Illinois.
Pfeiffer, C.C. e.a. (1974) Treatment of pyroluric schizophrenia (Malvaria) with large doses of pyridoxine and a dietary supplement of Zinc . J. Orthom. Psychiat. 3, 1974.
Pfeiffer, C.C. en E.H. Jenney (1974) Fingernail white spots: possible zinc deficiency. JAMA 228, 1974.
Pfeiffer, C.C. (1975) Mental and elemental nutrients: A physician guide to nutrition and health care. Keats Publishing, New Canaan, Connecticut.
Pfeiffer, C.C., Bacchi D. (1975) Copper, zinc, manganese, niacin and pyridoxine in the schizophrenias. Journal of Applied Nutrition 27, 9-39.
Pfeiffer, C.C. (1976) Psychiatric Hospital versus Brain BioCenter in diagnosis of Biochemical Imbalances. J. Orthom. Psych. 6, 28-34.
Pfeiffer, C.C. en B. Barnes (1981) Role of zinc, manganese, chromium, and vitamin deficiencies in birth defects. Intern. J. Environmental Studies 17, 43-57.
Pfeiffer C.C. (1981) Extra nutrients and mental illness. Biological Psychiatry. 16(9):797-799.
Pfeiffer, C.C. en E.R. Braverman (1982) Zinc, the brain and behavior. Biol. Psychiat 17, 513-532.
Pfeiffer, C.C. (1983) Zinc and manganese in the schizophrenias. J. Orth. Psychiatr. 12, 1982.
Pfeiffer C.C., LaMola S. (1983) Zinc and manganese in the schizophrenias. The Journal of Orthomolecular Psychiatry 12, 215-234.
Pfeiffer, C.C. (1984) Schizophrenia and wheat gluten enteropathy. Biological Psychiatry 19, 279-280.
Pfeiffer, C.C. (1986) Nahrstoff-Therapie bei psychischen Störungen. Haug-Verlag. pp. 59-80.
Pfeiffer, C.C. (1987) Mental illness and schizophrenia: The Nutrition Connection. Thorsons Pub. Group, Wellingborough.
Pfeiffer C.C. (1987) Nutrition and Mental Illness. Healing Arts Press, Rochester, Vermont, 1987.
Pfeiffer, C.C. (1988) Voeding en Psyche. Deventer: Ankh-Hermes.
Pfeiffer, C.C., L. Audette (1988) Histapenie around the world. OrthoMoleculair 3, 125-129.
Pfeiffer C.C., L. Audette (1988) Pyroluria-zinc and B6 deficiencies. International Clinical Nutrition Review 8, 107-109.
Pfeiffer, C.C. en L. Audette (1988) Pyrrolurie, Zink und B6-Defizienzen, Ortho-Molekular 5, 1988.
Pfeiffer, C.C. (1993) Nährstoff-Therapie bei psychischen Erkrankungen. Karl Haug Verlag, Heidelberg. 4e Auflage.
Prochazka, E. (2001) Pyrrolurie – das missing link. Zeitschrift Umweltmedizin 14-4-2001.
Rao, B.S., H.S. Narayanan en G.N. Reddy (1971) Investigations on urinary excretion of 3,4 dimethoxyphenylethylamine (the pink spot), the mauve factor and aromatic compounds in patients with schizophrenia. Indian J. of Medical Research 59, 455-460.
Ross, M.O. , U. Stölzel, M. Doss (200?) Arzneistoffe bei akuten hepatischen Porphyrien und Empfehlungen zur Anästhesie. Unknown 4 pp.
Russell C.S. (1972) Biosynthesis of porphyrins and the origin of the “mauve factor”. Journal of Theoretical Biology 35, 277-283.
Salomon, R.G., W. Sha, C. Brame, K. Kaur, G. Subbanagounder, J. O’Neil, H.F. Hof and L.J. Roberts (1999) Protein adducts of iso[4]levuglandin E2, a product of the isoprostane pathway, in oxidized low density lipoprotein. J. Biol. Chem. 274, 20271-20280.
Segermann, J., A. Hotze, H. Ulrich en G.S. Rao (1991) Effect of α-lipoic acid on the peripheral conversion of thyroxine to triiodothyronine and on serum lipid-, protein- and glucose levels. Arzneimittel Forschung 41, 1294-1298
Sohler A., Renz R.H., Smith S., et al. (1967) Significance of hydroxyskatole and mauve factor excretion in schizophrenia. International Journal of Neuropsychiatry pp. 327-331, July-August 1967.
Sohler A., Beck R., Noval J. (1970). Mauve factor re-identified as 2,4-dimethyl-3-ethylpyrrole and its sedative effect on the CNS. Nature 228,1318-1320.
Sohler A., Holsztynska E., Pfeiffer C.C. (1974) A rapid screening test for pyroluria; useful in distinguishing schizophrenic subpopulations. Journal of Orthomolecular Psychiatry 3, 273-279.
Sohler, A. (1975) Letter: Urinary kryptopyrrole. Biological Psychiatry 10, 685-686.
Sohler. A., C.C. Pfeiffer (1982) Vitamin B6 nutritional status of a psychiatric outpatient population. J. of Orthmol. Psych. 11, 81-86.
Somogyi, I., I. Huszak, I. Durko en T. Jardanhazy (1981) The effect of kryptopyrrole on the brain-activity of cats: a quantitative EEG-analysis. Z. Elektroenzephalogr. Elektromyogr. Verwandte Geb. 12, 212-215.
Strienz, Chr. (2007) Leben mit KPU – Kryptopyrrolurie W. Zuckschwerdt Verlag, München – Wien – New York 2007
Thome, K. (2002) Pyrrolurie – ein unbekanntes und doch verbreitetes Phänomen. WzG-Verlag 6 pp.
Vonnegut, M. (1975) The Eden Express. Praeger Publishers, Inc., New York, 1975.
Walker J.L. (1975) Neurological and behavioral toxicity of kryptopyrrole in the rat. Pharmacology Biochemistry and Behavior 3, 243-250.
Ward J.L. (1975) Relationship of kryptopyrrole, zinc and pyridoxine in schizophrenics. Journal of Orthomolecular Psychiatry 4, 27-31.
Watt, J.A., G.W. Ashcroft, R.J. Daly en J.R. Smythies (1969) Urine volume and pink spots in schizophrenia and health. Nature 221(184), 971-972.
Wettenberg L. (1972) Pharmacological and toxic effects of kryptopyrrole in mice. Journal of Orthomolecular Psychiatry 1, 141-144.
Wetterberg L. (1973) Pharmocological and toxic effects of kryptopyrrole in mice. Upsala Journal of Medical Sciences 78, 78-80.
Wettenberg, L. en B. Formgren (1976) Pharmacological and biochemical properties of kryptopyrrole and its oxidation products possibly related tot acute intermittent porphyria. Annals of Clinical Research 8 (suppl. 17), 162-167.
Wilson, C. (1996) Porphyrinopathies in the MCS community. Our toxic times 7, 1.
Zank, M. (2004) Gibt es Zusammenhänge zwischen Kryptopyrolurie, MCS, CFS, Fibromyalgie, KISS-Syndrom und Schleudertrauma? Umwelt-Echo jan. 2004, pp. 33-34.